Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about CR1: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
CR1 is a protein involved in neurodegeneration research. Key relationships include: associated with, regulates, co discussed. Associated with ALS, Aging, Als. Connected to 128 entities in the SciDEX knowledge graph.
No AI portrait yet
| Gene Symbol | CR1 |
| Full Name | Complement Component 1q Receptor |
| Chromosome | 1q32 |
| Protein Type | Receptor |
| Function | is a gene located on chromosome 1q32. |
| Primary Expression | Blood cells (erythrocytes, leukocytes), Brain (microglia, astrocytes), Kidney, Spleen |
| Molecular Weight | 250 kDa |
| Amino Acids | 1998 aa |
| Exons | 38 |
| Pathways | Apoptosis, Autophagy, Blood-Brain Barrier, Complement, Dysbiosis |
| UniProt ID | P08578 |
| NCBI Gene ID | 1378 |
| Ensembl ID | ENSG00000203797 |
| OMIM | 120600 |
| GeneCards | CR1 |
| Human Protein Atlas | CR1 |
| Associated Diseases | Aging, Als, Alzheimer, Alzheimer's disease, CELL SURVIVAL |
| Known Drugs/Compounds | Stem Cell Therapy |
| Interactions | ABCA7, Actin, AD, AGING, ALZHEIMER, ALZHEIMER DISEASE |
| KG Connections | 600 knowledge graph edges |
| Databases | GeneCardsHPASTRING |
Knowledge base pages for this entity
graph TD
CR1["CR1"]
Amyloid_beta_42["Amyloid-beta 42"]
CR1 -->|"regulates"| Amyloid_beta_42
complement_receptor_1["complement receptor 1"]
CR1 -->|"encodes"| complement_receptor_1
Neurodegeneration{"Neurodegeneration"}
CR1 -->|"associated with"| Neurodegeneration
Multiple_Sclerosis{"Multiple Sclerosis"}
CR1 -->|"associated with"| Multiple_Sclerosis
Als{"Als"}
CR1 -->|"associated with"| Als
Aging{"Aging"}
CR1 -->|"associated with"| Aging
Ms{"Ms"}
CR1 -->|"associated with"| Ms
Alzheimer{"Alzheimer"}
CR1 -->|"associated with"| Alzheimer
MICROGLIA["MICROGLIA"]
CR1 -->|"associated with"| MICROGLIA
SYNAPSE["SYNAPSE"]
CR1 -->|"associated with"| SYNAPSE
TAU["TAU"]
CR1 -->|"associated with"| TAU
Dementia{"Dementia"}
CR1 -->|"associated with"| Dementia
rs6656401["rs6656401"]
rs6656401 -->|"regulates"| CR1
APP["APP"]
APP -->|"associated with"| CR1
CLU["CLU"]
CLU -->|"associated with"| CR1
C1QA["C1QA"]
C1QA -->|"associated with"| CR1
CLU -->|"regulates"| CR1
C1S["C1S"]
C1S -->|"associated with"| CR1
CLUSTERIN["CLUSTERIN"]
CLUSTERIN -->|"regulates"| CR1
C1Q["C1Q"]
C1Q -->|"regulates"| CR1
GENES["GENES"]
GENES -->|"associated with"| CR1
RS6656401["RS6656401"]
RS6656401 -->|"associated with"| CR1
RS3919533["RS3919533"]
RS3919533 -->|"associated with"| CR1
CFH["CFH"]
CFH -->|"associated with"| CR1
style CR1 fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0| Target | Relation | Type | Str |
|---|---|---|---|
| ad_genetic_risk_loci:CR1 | data_in | dataset_row | 0.00 |
| benchmark_ot_ad_answer_key:CR1 | data_in | dataset_row | 0.00 |
| ds-db4a006ea647 | provides_data_for | dataset | 1.00 |
| ds-f50762b67605 | provides_data_for | dataset | 1.00 |
| ds-83b31ef18d49 | provides_data_for | dataset | 1.00 |
| ABeta42 | associated_with | biomarker | 0.85 |
| macrophages | expressed_in | cell_type | 0.80 |
| Cognitive Aging | risk_factor_for | phenotype | 0.80 |
| GENES | associated_with | gene | 0.80 |
| Dementia | associated_with | disease | 0.75 |
| Alzheimer | associated_with | disease | 0.75 |
| Als | associated_with | disease | 0.75 |
| Aging | associated_with | disease | 0.75 |
| Neurodegeneration | associated_with | disease | 0.75 |
| LRRK2 | associated_with | gene | 0.70 |
| MACROPHAGE | activates | cell_type | 0.70 |
| IBA1 | biomarker_for | gene | 0.70 |
| MICROGLIA | biomarker_for | cell_type | 0.70 |
| RELN | protects_against | gene | 0.70 |
| MICROGLIA | expressed_in | cell_type | 0.70 |
| NLRP3 | associated_with | gene | 0.70 |
| TREM2 | markers | gene | 0.70 |
| Down syndrome | associated_with | disease | 0.70 |
| neurons | expressed_in | cell_type | 0.70 |
| hippocampus | expressed_in | brain_region | 0.70 |
| complement receptor 1 | encodes | protein | 0.70 |
| Amyloid-beta 42 | regulates | protein | 0.70 |
| ALZHEIMER | associated_with | gene | 0.70 |
| PICALM | associated_with | gene | 0.70 |
| PSEN2 | regulates | gene | 0.70 |
| APOE | associated_with | gene | 0.70 |
| COMPLEMENT | associated_with | gene | 0.70 |
| stem cells | expressed_in | cell_type | 0.70 |
| Complement | associated_with | pathway | 0.70 |
| Multiple Sclerosis | associated_with | disease | 0.65 |
| MAPT | co_discussed | gene | 0.65 |
| SYNAPSE | associated_with | gene | 0.65 |
| Inflammation | associated_with | disease | 0.65 |
| MICROGLIA | associated_with | gene | 0.65 |
| TAU | associated_with | gene | 0.65 |
| ALS | activates | disease | 0.65 |
| LRRK2 | co_discussed | gene | 0.65 |
| Aging | biomarker_for | disease | 0.65 |
| Aging | activates | disease | 0.65 |
| Als | interacts_with | disease | 0.65 |
| Alzheimer | expressed_in | disease | 0.65 |
| TNF | co_discussed | gene | 0.65 |
| Als | activates | disease | 0.65 |
| Aging | expressed_in | disease | 0.65 |
| CTSD | co_discussed | gene | 0.65 |
| Source | Relation | Type | Str |
|---|---|---|---|
| ad_genetic_risk_loci:CR1 | data_in | dataset_row | 0.00 |
| benchmark_ot_ad_answer_key:CR1 | data_in | dataset_row | 0.00 |
| ds-83b31ef18d49 | data_in | dataset | 1.00 |
| ds-f50762b67605 | data_in | dataset | 1.00 |
| ALZHEIMER'S DISEASE | associated_with | gene | 1.00 |
| ds-db4a006ea647 | data_in | dataset | 1.00 |
| APOE | associated_with | gene | 0.90 |
| BIN1 | associated_with | gene | 0.82 |
| AMYLOID | associated_with | protein | 0.82 |
| Stem Cell Therapy | modulates | drug | 0.80 |
| ALZHEIMER DISEASE | associated_with | gene | 0.80 |
| CLU | associated_with | gene | 0.74 |
| TAU | associated_with | gene | 0.74 |
| APOE | protects_against | gene | 0.70 |
| CLU | regulates | gene | 0.70 |
| rs6656401 | regulates | gene | 0.70 |
| APP | associated_with | gene | 0.66 |
| TREM2 | associated_with | gene | 0.66 |
| INFLAMMATION | interacts_with | phenotype | 0.65 |
| INFLAMMATION | activates | phenotype | 0.65 |
| BDNF | co_discussed | gene | 0.65 |
| MONOCYTES | treats | cell_type | 0.65 |
| MICROGLIA | activates | gene | 0.60 |
| CYTOKINES | regulates | gene | 0.60 |
| ALZHEIMER | regulates | gene | 0.60 |
| AUTOPHAGY | regulates | gene | 0.60 |
| AGING | expressed_in | gene | 0.60 |
| ALZHEIMER | expressed_in | gene | 0.60 |
| AGING | activates | gene | 0.60 |
| GFP | activates | gene | 0.60 |
| EXERCISE | inhibits | gene | 0.60 |
| COMPLEMENT | regulates | gene | 0.60 |
| COMPLEMENT | inhibits | gene | 0.60 |
| GMNC | associated_with | gene | 0.60 |
| COMPLEMENT | activates | gene | 0.60 |
| GFP | expressed_in | gene | 0.60 |
| APOE | markers | gene | 0.60 |
| APOE | disrupts | gene | 0.60 |
| AUTOPHAGY | disrupts | pathway | 0.60 |
| C1S | associated_with | gene | 0.60 |
| CLUSTERIN | regulates | gene | 0.60 |
| C1Q | regulates | gene | 0.60 |
| IBA1 | expressed_in | gene | 0.60 |
| ZCWPW1 | interacts_with | gene | 0.60 |
| GAB2 | interacts_with | gene | 0.60 |
| PTK2B | interacts_with | gene | 0.60 |
| CD2AP | interacts_with | gene | 0.60 |
| MS4A6A | associated_with | gene | 0.60 |
| MS4A6A | interacts_with | gene | 0.60 |
| PICALM | interacts_with | gene | 0.60 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
neurodegeneration | 2026-04-27 | 3 hypotheses Top: 0.604
neurodegeneration | 2026-04-01 | 8 hypotheses Top: 0.782
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Microglial TREM2 Agonist In Vivo Efficacy | validation | Alzheimer's Disease | 0.450 | 0.50 | mouse | proposed | $360,000 |
| TREM2 Agonist Therapy for Parkinson's Disease — Experimental Design | validation | Parkinson's Disease | 0.450 | 0.50 | mouse | proposed | $280,000 |
| TREM2 Function in Alzheimer's Disease — From Risk Variant to Therapeut | validation | Alzheimer's Disease | 0.450 | 0.50 | human | proposed | $2,960,000 |
| s:** - GPR32 knockout in microglia should worsen neuroinflammation if | falsification | Neuroinflammation | 0.400 | 0.50 | cell_line | proposed | $80,000 |
| Proposed experiment from debate on Synaptic pruning by microglia in ea | falsification | Neuroinflammation | 0.400 | 0.50 | mouse | proposed | $240,000 |
| DLB Treatment Response Biomarkers — Predicting Cholinesterase Inhibito | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $6,550,000 |
| FTD Microglia Role: Protective vs Destructive Mechanism Study | validation | Neuroinflammation | 0.400 | 0.50 | human | proposed | $2,960,000 |
| Microglial Aging and Immune Memory in Neurodegeneration — Training the | validation | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $2,960,000 |
| Microglial Contributions to Huntington's Disease Pathogenesis | validation | Neuroinflammation | 0.400 | 0.50 | human | proposed | $2,960,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Fractalkine Enhances Hematoma Resolution and Improves Neurological Function via [PMID:37465997] | Chen X, He X, Xu F, Xu N, Sharifi NH, Zh | Stroke | 2023 | 1 |
| Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Ca [PMID:35642214] | Wang M, Pan W, Xu Y, Zhang J, Wan J, Jia | J Inflamm Res | 2022 | 1 |
| CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases. [PMID:34492237] | Subbarayan MS, Joly-Amado A, Bickford PC | Pharmacol Ther | 2022 | 1 |
| Microglia in neurodegeneration. [PMID:30258234] | Hickman S, Izzy S, Sen P, Morsett L, El | Nat Neurosci | 2018 | 1 |
| How neuroinflammation contributes to neurodegeneration. [PMID:27540165] | Ransohoff RM | Science | 2016 | 1 |
| CX3CL1/CX3CR1 axis dysregulation contributes to epileptogenic mechanisms in foca [PMID:41863015] | Lei Lei; Shengyu Yang; Yinchao Li; Jiaha | Acta neuropathologica communic | 2026 | 0 |
| Constitutive expression of CX3CR1-BAC-Cre introduces minimal off-target effects [PMID:41924777] | Mroue-Ruiz FH, Desai B, Garvin MM, Shehu | Biochemical and biophysical re | 2026 | 0 |
| Systems-level molecular and immunological evidence identifies Th17/Treg modulati [PMID:41788408] | ["Li X", "Li X", "Chen S", "Wang L", "Xi | Frontiers in aging neuroscienc | 2026 | 0 |
| Multimodal tumor thermal therapy enhances antitumor immunity by expanding tumor- [PMID:41799205] | ["Wang S", "Wang Y", "Zhang Y", "Zhang Z | Theranostics | 2026 | 0 |
| Peripheral cancer attenuates amyloid pathology in Alzheimer's disease via cystat [PMID:41576952] | Li X, Tang X, Zeng J, Duan L, Hou Z et a | Cell | 2026 | 0 |
| [Corrigendum] Influence of aspirin on the CX3CL1/CX3CR1 signaling pathway in acu [PMID:41930567] | Zhang Z, Yang W, Ying R, Shi Y, Jiang H | Int J Mol Med | 2026 | 0 |
| CX3CR1-T280M polymorphism and end-stage renal disease development in chronic kid [PMID:41932952] | Matteo Gatti; Ivano Baragetti; Andrea Ba | Scientific reports | 2026 | 0 |
| SYK-dependent lipid handling in monocyte-derived macrophages governs functional [PMID:41831796] | ["Zhao Y", "Hu H", "Wang J", "Hu Y", "Ya | Brain research bulletin | 2026 | 0 |
| Microglial Lag3 Drives α-Synuclein-induced Neurotoxic Activated (A1) Astrocytes [PMID:41542562] | ["Yang X", "Kumbhar R", "Seo B", "Ha S", | bioRxiv : the preprint server | 2026 | 0 |
| Conserved ductular reaction mechanisms in biliary atresia and PSC derived from s [PMID:41903685] | Schofield A, Kamath BM, MacParland SA, T | Cellular and molecular gastroe | 2026 | 0 |
| Identification of suicide brain transcriptomic signatures using meta-analysis of [PMID:41916959] | Sokolov AV, Lafta MS, Jokinen J, Schiöth | Translational psychiatry | 2026 | 0 |
| Helper T cells and chemokines in elderly asthma - Mechanisms of airway inflammat [PMID:41805218] | ["Wu Y"] | Biomolecules & biomedicine | 2026 | 0 |
| Identification of metabolism and inflammation-related biomarkers and potential d [PMID:41781900] | ["Chen Y", "Zhang M", "Qiao L", "Lu F", | BMC psychiatry | 2026 | 0 |
| Chemokine Networks in Blood-Brain Barrier Regulation: Bidirectional Mechanisms, [PMID:41897331] | ["Wu Q", "Miao Z", "Lei W", "Wu X", "Zha | Biomolecules | 2026 | 0 |
| Two-Sample Bidirectional Mendelian Randomization Analysis of the Causal Relation [PMID:41878553] | ["Niu W", "Li J", "Jia H", "Wang L", "Xu | Clinical, cosmetic and investi | 2026 | 0 |
Multi-agent debates referencing this entity
active · Rounds: 4 · Score: 0.64 · 2026-04-28
closed · Rounds: 4 · Score: 0.40 · 2026-04-27
closed · Rounds: 4 · Score: 0.89 · 2026-04-06
Hypotheses and analyses mentioning CR1 in their description or question text
Score: 0.570 · neuroinflammation · 2026-04-22
## Mechanistic Overview CX3CR1-Negative Trem2-High Microglial Subset Mediates Female Resilience via Estrogen Receptor-al
Score: 0.563 · neurodegeneration · 2026-04-02
## Mechanistic Overview Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators starts from the claim t
Score: 0.540 · neurodegeneration · 2026-04-22
## Mechanistic Overview Soluble CX3CL1 cleavage by ADAM proteases disengages fractalkine signaling, removing the neurona
Score: 0.530 · pharmacology · 2026-04-21
## Mechanistic Overview CX3CR1-Targeted AntimiR-155 Oligonucleotides for Microglial Priming Reversal starts from the cla
Score: 0.491 · neuroscience · 2026-04-21
## Mechanistic Overview GluN2B-Regulated Microglial Phagocytosis of Tau Aggregates via CX3CR1 Signaling starts from the
Score: 0.477 · biomarkers · 2026-04-22
## Mechanistic Overview CX3CR1 PET with Nano-bodies for Microglial Surveillance State Mapping starts from the claim that
Score: 0.105 · neurodegeneration · 2026-04-18
## Mechanistic Overview TREM2 Agonism with CX3CR1 Antagonism for Microglial Homeostasis starts from the claim that modul